Sylvester Comprehensive Cancer Center

  • 20221388 - Alperstein Warren

  • Investigator:
    Warren Alperstein
    RCname Email

    		Coordinator:

    IRB: 20221388

    		SDG: Peds
    Disease Site(s):

    Leukemia, not otherwise specified
    Sponsor: UNIVERSITY OF FLORIDA

    Enrolling Sites:

    Sylvester
    Title:

    Phase I/II trial: Engineered Donor Graft (Orca-Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients with Hematologic Malignancies (HM)
    Eligibility Criteria - NCT05322850 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231146 - Alperstein Warren

  • Investigator:
    Warren Alperstein
    RCname Email

    		Coordinator:

    IRB: 20231146

    		SDG: Peds
    Disease Site(s):

    Leukemia, Other
    Sponsor: NIH

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
    Eligibility Criteria - NCT05600426 *This information has been extracted from " www.clinicaltrials.gov"

  • AGCT1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:

    IRB: 20170605

    		SDG: Peds
    Disease Site(s):

    Other Female Genital,Other Male Genital,Ovary
    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
    Eligibility Criteria - NCT03067181 *This information has been extracted from " www.clinicaltrials.gov"

  • ANBL 1821 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:

    IRB: 20190652

    		SDG: Peds
    Disease Site(s):

    Brain and Nervous System
    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed, Refractory or Progressive Neuroblastoma
    Eligibility Criteria - NCT03794349 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210407 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:

    IRB: 20210407

    		SDG: Peds
    Disease Site(s):

    Leukemia, Other
    Sponsor: NOVARTIS

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.
    Eligibility Criteria - NCT03601442 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230224 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:

    IRB: 20230224

    		SDG: Peds
    Disease Site(s):

    Soft Tissue
    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
    Eligibility Criteria - NCT05304585 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230304 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:

    IRB: 20230304

    		SDG: Peds
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: COG

    Enrolling Sites:

    Sylvester
    Title:

    A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
    Eligibility Criteria - NCT04759586 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231101 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:

    IRB: 20231101

    		SDG: Peds
    Disease Site(s):

    Leukemia, not otherwise specified
    Sponsor: COG

    Enrolling Sites:

    Sylvester
    Title:

    A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
    Eligibility Criteria - NCT05457556 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240629 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:

    IRB: 20240629

    		SDG: Peds
    Disease Site(s):

    Stomach
    Sponsor: COG

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
    Eligibility Criteria - NCT06172296 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210234 - Dhir Aditi

  • Investigator:
    Aditi Dhir
    RCname Email

    		Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20210234

    		SDG: Peds
    Disease Site(s):

    Soft Tissue
    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
    Eligibility Criteria - NCT04388839 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240070 - Gampel Bradley

  • Investigator:
    Bradley Gampel
    RCname Email

    		Coordinator:

    IRB: 20240070

    		SDG: Peds
    Disease Site(s):

    Brain and Nervous System
    Sponsor: COG

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
    Eligibility Criteria - NCT04684368 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240573 - Gampel Bradley

  • Investigator:
    Bradley Gampel
    RCname Email

    		Coordinator:

    IRB: 20240573

    		SDG: Peds
    Disease Site(s):

    Brain and Nervous System
    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester
    UMH
    Title:

    A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
    Eligibility Criteria - NCT04939597 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230032 - McCrea Heather

  • Investigator:
    Heather McCrea
    RCname Email

    		Coordinator:

    IRB: 20230032

    		SDG: Peds
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
    Eligibility Criteria - NCT05956821 *This information has been extracted from " www.clinicaltrials.gov"